Alexion Pharmaceuticals, Inc. (ALXN): Extremely Expensive Drugs for Extremely Rare Diseases

Page 3 of 3

The Foolish Bottom Line

In my opinion, Alexion is an interesting case study in the biotech industry. It has built a $21 billion business on a single, expensive drug which is used to diagnose some of the rarest diseases in the world. It also looks to continue this business model in the future, with the majority of its new treatments geared towards very rare diseases.

This is a stark contrast from other pharmaceutical companies, which often fight tooth and nail to introduce cutting edge treatments for major maladies, such as diabetes, cancer or hepatitis. Based on its second quarter numbers, Alexion’s future top and bottom line growth looks strong, and positive acquisition buzz could keep investors interested.

Leo Sun has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article Extremely Expensive Drugs for Extremely Rare Diseases originally appeared on Fool.com and is written by Leo Sun.

Leo is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 3 of 3